Opko Health Stock Price, News & Analysis

OPKO Health (NASDAQ: OPK) and Entera Bio announced their abstract for oral OPK-88006, a novel dual GLP-1/glucagon peptide treatment, has been selected for presentation at ENDO 2025 in San Francisco. The treatment is being developed as both a once-daily tablet and a weekly subcutaneous injection for patients with obesity and metabolic disorders.

The oral program combines OPKO's long-acting oxyntomodulin analog with Entera's N-Tab™ technology. The companies plan to file an IND application with the FDA later in 2025, followed by Phase 1 clinical studies. The presentation will showcase new pharmacologic and pharmacokinetic in vivo data at the conference on July 13, 2025.

OPKO Health's subsidiary ModeX Therapeutics has formed a Scientific Advisory Board comprising four distinguished leaders in immunology and oncology: Drs. John Heymach, Ronald Levy, Myron Cohen, and Rafi Ahmed. The board will provide expertise for ModeX's development of next-generation multispecific antibodies and vaccines using its MSTAR platform technology. The company currently has two assets in clinical trials and multiple pre-IND assets. The advisory board members bring extensive experience in immunology, cancer treatment, HIV research, and vaccine development. ModeX's platform focuses on creating multispecific medicines that can target multiple disease pathways simultaneously, aiming to address complex conditions that are currently untreatable with single-target approaches.

OPKO Health (NASDAQ: OPK) has announced its participation in two upcoming investor conferences. The company will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq on May 20 in New York City, featuring one-on-one investor meetings and a fireside discussion at 9:00 a.m. ET. Additionally, OPKO will participate in the Jefferies Global Healthcare Conference from June 3-5 at the Marriott Marquis in New York City, with investor meetings and a fireside chat scheduled for June 4th at 11:05 a.m. ET. Both fireside discussions will be webcast live and available for replay on OPKO Health's website.

OPKO Health reports Q1 2025 financial results with key developments in its business portfolio. The company signed a definitive agreement to sell BioReference's oncology testing assets to Labcorp for up to $225 million. OPKO partnered with Entera Bio to develop an oral GLP-1/glucagon tablet for obesity treatment, with OPKO holding a 60% stake.

Financial highlights include consolidated revenues of $149.9 million, down from $173.7 million in Q1 2024. The company posted a net loss of $67.6 million ($0.10 per share), improving from $81.8 million ($0.12 per share) year-over-year.

Notable progress includes Merck's Phase 1 trial of an Epstein-Barr virus vaccine and ModeX's advancement of four clinical candidates. The Board authorized an additional $100 million for stock repurchase, bringing total capacity to $200 million. Cash position stands strong at $449.7 million as of March 31, 2025.

OPKO Health (NASDAQ: OPK) has announced it will release its Q1 2025 financial and operating results on April 30, 2025 after U.S. market close. The company's senior management will host a conference call and live audio webcast at 4:30 p.m. Eastern time to discuss the results and provide financial guidance.

Participants can pre-register for the conference call through a provided link to receive a unique PIN for immediate access. Those unable to pre-register can dial 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast replay will be available approximately one hour after the call until May 7, 2025.

NextPlat Corp (NASDAQ: NXPL) announced it will pause certain initiatives within its e-Commerce development program due to increased US/China tariffs on US-produced goods. The company is specifically halting plans for its Florida Sunshine brand of vitamins and supplements in the Chinese market, as the tariffs would significantly impact import costs and competitive positioning against local products.

Despite these challenges, NextPlat will continue selling OPKO Health Europe (OPKO) products in China, including nutraceuticals, supplements, and pet care items, as these are not US-produced and therefore not subject to the additional tariffs. The company is exploring opportunities to sell Florida Sunshine products in other markets.

OPKO Health (NASDAQ: OPK) has announced a $100 million increase to its existing share repurchase program, bringing the total program capacity to $200 million. The company has already repurchased approximately $41 million of common stock since the program's initial authorization in July 2024.

The expanded buyback program, representing about 14% of shares outstanding at current price levels, will be executed through various methods including open market purchases, block trades, and accelerated share repurchase transactions. OPKO had approximately 671.6 million shares outstanding as of February 24, 2025.

The company plans to fund the repurchases from existing cash reserves and future cash flows. The program has no time limit and can be modified or suspended at management's discretion based on market conditions and other factors.

OPKO Health (NASDAQ: OPK) and Entera Bio have formed a collaboration agreement to develop the first oral dual agonist GLP-1/glucagon peptide tablet for treating obesity and metabolic disorders. The program combines OPKO's long-acting oxyntomodulin analog (OPK-88006) with Entera's N-Tab™ technology.

The partnership structure gives OPKO a 60% ownership stake and Entera 40%, with corresponding cost-sharing responsibilities. OPKO has purchased 3,685,226 Entera shares at $2.17 per share, with proceeds funding Entera's Phase 1 development costs. After Phase 1, Entera can maintain its 40% stake by continuing funding, or opt-out to retain 15% ownership while OPKO increases to 85%.

The companies reported favorable pharmacodynamic, pharmacokinetic, and bioavailability data in September 2024 and plan to file an FDA Investigational New Drug application later in 2025. The treatment aims to suppress appetite, induce weight loss, and provide cardioprotective and anti-fibrotic benefits through its novel dual-action mechanism.

Labcorp (NYSE: LH) has announced an agreement to acquire select assets of BioReference Health's oncology and oncology-related clinical testing services from OPKO Health. The transaction, valued at up to $225 million, includes $192.5 million at closing and a potential $32.5 million performance-based earnout.

The acquired assets generate $85-100 million in annual revenue and will expand Labcorp's oncology diagnostic testing portfolio across the United States. The deal is expected to be earnings accretive in the first year and close in the second half of 2025.

Post-acquisition, BioReference Health will maintain its core clinical testing operations in the New York and New Jersey region, including its 4Kscore franchise, which generated approximately $300 million in revenue for 2024.